An exploratory pharmacokinetic/pharmacodynamic study of CERC 301 in inpatients with major depressive disorder.

Trial Profile

An exploratory pharmacokinetic/pharmacodynamic study of CERC 301 in inpatients with major depressive disorder.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs CERC 301 (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Cerecor
  • Most Recent Events

    • 25 Mar 2015 New trial record
    • 20 Mar 2015 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top